ReviewDiabetes, obesity & metabolism2025
Cardiac troponin at the point of care in acute and chronic coronary syndromes.
Review in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Biomarkers for cardiovascular-kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment.Diabetes, obesity & metabolism · 2025Article
- Cardiac troponin at the point of care in acute and chronic coronary syndromes.Diabetes, obesity & metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-sensitivity cardiac troponin (hs-cTn) assays are integral to the assessment of patients with acute chest pain where prompt and accurate diagnosis of myocardial infarction enables timely delivery of potentially life-saving treatment. In the Emergency Department, implementation of central laboratory hs-cTn assays has reduced length of stay and unnecessary hospital admission. Recently hs-cTn assays have become available on point-of-care (POC) platforms that have equivalent analytical and diagnostic performance to central laboratory platforms but can deliver results more rapidly to guide decisions in real-time. These assays have the potential to further accelerate care in the Emergency Department and to facilitate the assessment of patients with suspected acute coronary syndromes in pre-hospital settings, primary care and the out-patient clinic. Greater accessibility to testing could broaden the role of hs-cTn to improve the risk stratification of patients with new onset exertional angina and chronic coronary syndromes. Whilst hs-cTn assays are already available for use at the point-of-care, prospective studies are required to determine the clinical and cost-effectiveness of testing in patients with acute and chronic coronary syndromes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.